Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 74, Issue 22, Pages 4171-4187Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-017-2575-0
Keywords
p53 mutation; Targeted therapies; Survival pathway; Gain of function
Categories
Funding
- Komen SAB
- Breast Cancer Research Foundation
- John Charles Cain Distinguished Chair Award
- John F. and Julie Young Award
- Cancer Center Support Grant [5 P30 CA016672-38]
Ask authors/readers for more resources
The tumor suppressor p53 is lost or mutated in approximately half of human cancers. Mutant p53 not only loses its anti-tumor transcriptional activity, but also often acquires oncogenic functions to promote tumor proliferation, invasion, and drug resistance. Traditional strategies have been taken to directly target p53 mutants through identifying small molecular compounds to deplete mutant p53, or to restore its tumor suppressive function. Accumulating evidence suggest that cancer cells with mutated p53 often exhibit specific functional dependencies on secondary genes or pathways to survive, providing alternative targets to indirectly treat p53-mutant cancers. Targeting these genes or pathways, critical for survival in the presence of p53 mutations, holds great promise for cancer treatment. In addition, mutant p53 often exhibits novel gain-of-functions to promote tumor growth and metastasis. Here, we review and discuss strategies targeting mutant p53, with focus on targeting the mutant p53 protein directly, and on the progress of identifying genes and pathways required in p53-mutant cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available